Presa Maximiliano, Chen Yi-Guang, Grier Alexandra E, Leiter Edward H, Brehm Michael A, Greiner Dale L, Shultz Leonard D, Serreze David V
The Jackson Laboratory, Bar Harbor, ME 04609;
Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI 53226; and.
J Immunol. 2015 Oct 1;195(7):3011-9. doi: 10.4049/jimmunol.1402446. Epub 2015 Aug 17.
NOD-scid.Il2rg(null) (NSG) mice are currently being used as recipients to screen for pathogenic autoreactive T cells in type 1 diabetes (T1D) patients. We questioned whether the restriction of IL-2R γ-chain (Il-2rγ)-dependent cytokine signaling only to donor cells in NSG recipients differently influenced the activities of transferred diabetogenic T cells when they were introduced as a monoclonal/oligoclonal population versus being part of a polyclonal repertoire. Unexpectedly, a significantly decreased T1D transfer by splenocytes from prediabetic NOD donors was observed in Il-2rγ(null)-NSG versus Il-2rγ-intact standard NOD-scid recipients. In contrast, NOD-derived monoclonal/oligoclonal TCR transgenic β cell-autoreactive T cells in either the CD8 (AI4, NY8.3) or CD4 (BDC2.5) compartments transferred disease significantly more rapidly to NSG than to NOD-scid recipients. The reduced diabetes transfer efficiency by polyclonal T cells in NSG recipients was associated with enhanced activation of regulatory T cells (Tregs) mediated by NSG myeloid APC. This enhanced suppressor activity was associated with higher levels of Treg GITR expression in the presence of NSG than NOD-scid APC. These collective results indicate NSG recipients might be efficiently employed to test the activity of T1D patient-derived β cell-autoreactive T cell clones and lines, but, when screening for pathogenic effectors within polyclonal populations, Tregs should be removed from the transfer inoculum to avoid false-negative results.
NOD-scid.Il2rg基因敲除(NSG)小鼠目前被用作受体,以筛选1型糖尿病(T1D)患者中的致病性自身反应性T细胞。我们质疑,在NSG受体中,仅将依赖白细胞介素-2受体γ链(Il-2rγ)的细胞因子信号传导限制于供体细胞,当将致糖尿病T细胞作为单克隆/寡克隆群体引入与作为多克隆库的一部分引入时,是否会对其活性产生不同影响。出乎意料的是,与Il-2rγ完整的标准NOD-scid受体相比,在Il-2rγ基因敲除的NSG受体中,观察到来自糖尿病前期NOD供体的脾细胞对T1D的转移明显减少。相反,NOD来源的CD8(AI4、NY8.3)或CD4(BDC2.5)区室中的单克隆/寡克隆TCR转基因β细胞自身反应性T细胞向NSG转移疾病的速度明显快于向NOD-scid受体转移的速度。NSG受体中多克隆T细胞的糖尿病转移效率降低与NSG髓样抗原呈递细胞(APC)介导的调节性T细胞(Tregs)激活增强有关。这种增强的抑制活性与在存在NSG的情况下Treg糖皮质激素诱导的肿瘤坏死因子受体(GITR)表达水平高于NOD-scid APC有关。这些综合结果表明,NSG受体可能有效地用于测试T1D患者来源的β细胞自身反应性T细胞克隆和系的活性,但是,在筛选多克隆群体中的致病效应子时,应从转移接种物中去除Tregs,以避免假阴性结果。